BMEA — Biomea Fusion, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1840439 ·
Last close
$0.49
Market Cap
$35.47M
52W High
$2.24
52W Low
$0.46
ADV30
2,125,522
Next earnings
2026-11-10
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -12,963,000 | -6,183,000 | 28,097,000 | 26,403,000 | 20,511,000 |
| Jun 2026 | 0 | — | -12,766,000 | -8,328,000 | 36,873,000 | 34,824,000 | 24,736,000 |
| Mar 2026 | 0 | — | -12,774,000 | -12,415,000 | 46,385,000 | 44,693,000 | 27,666,000 |
| Dec 2025 | 0 | — | -11,719,000 | 4,612,000 | 58,572,000 | 55,812,000 | 29,020,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-44,072,000
Investing CF
$550,000
Financing CF
$23,283,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.65
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-475,974,000
Inventory
—
Receivables
$22,000
ST Investments
—
EBIT TTM
$-50,222,000
Pretax Income TTM
$-22,314,000
Interest Exp TTM
—
Analysts
6
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -81,307,000 | -61,797,000 | 58,572,000 | 29,020,000 | 29,552,000 | -70,371,000 |
| Dec 2024 | 0 | -144,070,000 | -138,426,000 | 79,938,000 | 28,365,000 | 51,573,000 | -119,894,000 |
| Dec 2023 | 0 | -126,135,000 | -117,255,000 | 199,927,000 | 30,690,000 | 169,237,000 | -96,592,000 |
| Dec 2022 | 0 | -83,634,000 | -81,828,000 | 129,307,000 | 20,768,000 | 108,539,000 | -62,417,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-32,538,000
OpCashFlow TTM
—
Assets (Latest)
$36,873,000
Forward EPS
$-0.91
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $0.50 · spot: $0.53 · call volume: 434 · put volume: 21
Expected Move to 2027-01-15:
±$0.35
(66.04%) —
implied range
$0.18 –
$0.88
· ATM straddle on $0.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| OSTX | OS Therapies Inc | $34.86M | $0.74 | — |
| GRCE | Grace Therapeutics, Inc. | $36.18M | $1.72 | — |
| SER | Serina Therapeutics, Inc. | $36.27M | $1.37 | — |
| CNTB | Connect Biopharma Holdings Ltd | $36.45M | $0.58 | — |
| VERU | VERU INC. | $36.49M | $2.14 | — |
News headlines (Yahoo Finance, 1h cache)
Biomea Fusion to Participate in Upcoming Investor Conferences
2026-11-12 21:01 · Yahoo
Biomea Fusion Reports Third Quarter 2026 Financial Results and Corporate Highlights
2026-11-10 21:05 · Yahoo
Biomea Fusion Announces Poster Presentation of Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist, at ObesityWeek® 2026
2026-11-10 12:00 · Yahoo
Biomea Fusion’s BMF-650 Shows Up to 6.1% Weight Loss in Early GLP-1 Study
2026-10-14 01:02 · Yahoo
Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist
2026-10-13 20:08 · Yahoo
Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist
2026-10-12 20:30 · Yahoo
Biomea Fusion Announces Termination of Proposed Public Offering of Securities
2026-09-23 11:03 · Yahoo
Biomea Fusion Announces Proposed Public Offering of Securities
2026-09-22 20:05 · Yahoo
After Golden Cross, Biomea Fusion, Inc. (BMEA)'s Technical Outlook is Bright
2026-09-04 13:55 · Yahoo
Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes
2026-08-24 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.